Volume 7, Number 5—October 2001
Cost-Effectiveness of a Potential Vaccine for Coccidioides immitis
|Age||Strategyb||Life expectancy (years; days)||Incremental life expectancyc (days)||Quality-adjusted life expectancy (years; days)||Incremental quality-adjusted life expectancyc (days)||Cost ($)||Incremental costd ($)||CE ratio ($/QALY)e|
|<17||No vaccine||28; 160.15||-||25; 172.98||-||35,196||-||-|
|Screen/vaccinate||28; 160.58||0.43||25. 174.66||1.68||35,187||-9||-|
|Vaccinate||28; 160.62||0.04||25; 174.84||0.18||35,163||-24||Dominates|
|18-65||No vaccine||21; 272.68||-||18; 60.12||-||47,477||-||-|
|Screen/vaccinate||21; 272.82||0.14||18; 60.65||0.53||47,568||90||62,000|
|Vaccinate||21; 272.84||0.02||18; 60.70||0.05||47,601||33||235,000|
aLife expectancy and costs are discounted at 3% per year.
bStrategies are ranked by effectiveness, from the least to the most effective, for each age group.
cAll incremental values compare an alternative with the next most effective strategy (e.g., cost [screen/vaccinate] - cost [no vaccine] = incremental cost [screen/vaccinate over no vaccine]).
dNegative values reflect cost savings compared to the next most effective strategy.
eCost-effectiveness ratio: refer to Appendix for formula. A strategy dominates if it is both more effective and less expensive than all comparison strategies.
Screen/vaccinate = vaccination of susceptible persons identified through a screening skin test; vaccinate = vaccination of all persons.